Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
17.04.25
/
50%
€6.75
Target price
17.04.26
€12.32
Performance (%)
-20.74%
Price
29.12.25
€5.45
Summary
This prediction is currently active. The prediction for Myriad Genetics disappoints with a performance of -20.74%. This prediction currently runs until 17.04.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | -2.586% | -2.586% |
| iShares Core DAX® | 0.323% | 2.208% |
| iShares Nasdaq 100 | 0.145% | -0.987% |
| iShares Nikkei 225® | 0.091% | -1.421% |
| iShares S&P 500 | 0.371% | -0.469% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat